Keyphrases
Unresectable Hepatocellular Carcinoma
100%
Progression-free Survival
100%
Clinical Practice
100%
Immune-related Adverse Events
100%
Durvalumab
100%
Tremelimumab
100%
Clinical Factors
50%
Bevacizumab Treatment
50%
Atezolizumab Plus Bevacizumab
50%
Multivariate Analysis
25%
Observation Period
25%
Hepatocellular Carcinoma Patients
25%
Barcelona Clinic Liver Cancer
25%
Hazard Ratio
25%
Univariate Analysis
25%
Prognostic Factors
25%
Later-line Treatment
25%
Objective Response
25%
Disease Control Rate
25%
Median Progression-free Survival
25%
Male Patients
25%
Event Occurrence
25%
Response Control
25%
Clinical Prognostic Factors
25%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Progression Free Survival
100%
Immunotherapy
100%
Durvalumab
100%
Ticilimumab
100%
Adverse Event
80%
Atezolizumab
40%
Bevacizumab
40%
Prognostic Factor
40%
Multivariate Analysis
20%
Liver Cancer
20%
Hazard Ratio
20%
Cancer Staging
20%
Univariate Analysis
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Progression Free Survival
100%
Immunotherapy
100%
Durvalumab
100%
Tremelimumab
100%
Adverse Event
80%
Atezolizumab
40%
Bevacizumab
40%
Cancer Staging
20%
Liver Cancer
20%
Diseases
20%
Agricultural and Biological Sciences
Bevacizumab
100%
Tremelimumab
100%
Multivariate Analysis
50%
Veterinary Science and Veterinary Medicine
Hepatocellular Carcinoma
100%
Liver Cancer
33%
Cancer Stages
33%